Valuation: Amplia Therapeutics Limited

Market Cap 59.03M 41.17M 36.34M 34.38M 31.18M 58.45M 3.95B 412M 159M 2.02B 155M 151M 6.49B P/E 2027 *
-5x
P/E 2028 * -16.4x
Enterprise Value 41.13M 28.69M 25.32M 23.95M 21.72M 40.73M 2.75B 287M 111M 1.41B 108M 105M 4.52B EV / Sales 2027 *
-
EV / Sales 2028 * 3.75x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 day-4.17%
1 week-8.00%
Current month-14.81%
1 month-20.69%
3 months-23.33%
6 months-53.06%
Current year-23.33%
1 week 0.12
Extreme 0.115
0.12
1 month 0.12
Extreme 0.115
0.15
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.28
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 2022-12-04
Director of Finance/CFO - 2021-09-30
Chief Tech/Sci/R&D Officer - 2025-05-11
Director TitleAgeSince
Director/Board Member 70 2015-09-01
Chairman - 2018-05-24
Chairman - 2026-06-29
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/25 Exercice

Chairman

750,000 0.1933%
9/8/25 Free

Founder

447,000 0.1152%
9/8/25 Exercice

Director

535,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%-8.00%-25.81%+41.98% 43.23M
-0.70%-4.28%+52.62%+86.42% 71.81B
+0.45%-0.82%+38.81%+84.19% 60.06B
+2.71%+4.17%+34.21%+23.73% 27.93B
-1.73%-4.30%-18.37%+357.94% 25.7B
-0.51%-2.28%+0.48%-9.27% 24.89B
+0.65%+1.67%+26.47%-7.62% 20.92B
+3.46%+3.02%+158.90%+337.81% 15.04B
+0.48%+0.86%+44.56%+168.42% 14.46B
+1.23%-0.83%-6.81%+509.41% 13.87B
Average +0.20%-1.65%+30.51%+159.30% 27.47B
Weighted average by Cap. +0.32%-1.84%+36.76%+128.56%

Financials

2027 *2028 *
Net sales - 9.5M 6.63M 5.85M 5.53M 5.02M 9.41M 636M 66.37M 25.58M 325M 24.88M 24.34M 1.04B
Net income -11.6M -8.09M -7.14M -6.76M -6.13M -11.49M -776M -81.04M -31.24M -396M -30.38M -29.72M -1.28B -4.1M -2.86M -2.52M -2.39M -2.17M -4.06M -274M -28.65M -11.04M -140M -10.74M -10.5M -451M
Net Debt -17.9M -12.49M -11.02M -10.42M -9.45M -17.73M -1.2B -125M -48.2M -612M -46.88M -45.86M -1.97B -23.4M -16.32M -14.4M -13.63M -12.36M -23.17M -1.57B -163M -63.01M -800M -61.29M -59.95M -2.57B
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
26-09-29 A$0.1150 -4.17% 306,371
26-09-28 A$0.1200 0.00% 174,236
26-09-25 A$0.1200 0.00% 575,779
26-09-24 A$0.1200 0.00% 8,789
26-09-23 A$0.1200 -4.00% 250,774
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1150AUD
Average target price
0.4200AUD
Spread / Average Target
+265.22%

Quarterly revenue - Rate of surprise